MEIP - MEI Pharma Inc
IEX Last Trade
3.1
-0.160 -5.161%
Share volume: 27,061
Last Updated: Fri 30 Aug 2024 09:59:45 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$3.26
-0.16
-4.91%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | |
| Report Date | 2022-09-08 | 2022-11-14 | 2023-02-09 | 2023-05-11 | 2023-09-26 | 2023-11-09 | 2024-02-13 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 177.840 M | 163.583 M | 147.599 M | 134.187 M | 120.809 M | 101.251 M | 78.538 M | 71.260 M | |
| Current Assets | 167.126 M | 148.907 M | 133.445 M | 120.483 M | 107.528 M | 88.422 M | 66.172 M | 59.366 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 3.830 M | 2.782 M | 3.568 M | 3.867 M | 6.750 M | 6.220 M | 6.692 M | 2.814 M | |
| Short Term Investments | 3.830 M | 2.782 M | 3.568 M | 3.867 M | 6.750 M | 6.220 M | 6.692 M | 2.814 M | |
| Total Receivables | 10.044 M | 7.758 M | 5.704 M | 4.580 M | 85.000 K | 0.000 | 0.000 | 0.000 | |
| Current Cash | 153.252 M | 138.367 M | 124.173 M | 112.036 M | 100.693 M | 82.202 M | 59.480 M | 56.552 M | |
| Total Non-current Assets | 10.714 M | 14.676 M | 14.154 M | 13.704 M | 13.281 M | 12.829 M | 12.366 M | 11.894 M | |
| Property Plant Equipment | 1.660 M | 1.624 M | 1.456 M | 1.366 M | 1.309 M | 1.229 M | 1.144 M | 1.058 M | |
| Other Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 177.840 M | 163.583 M | 147.599 M | 134.187 M | 120.809 M | 101.251 M | 78.538 M | 71.260 M | |
| Total liabilities | 125.427 M | 126.275 M | 99.225 M | 99.833 M | 96.185 M | 19.890 M | 19.050 M | 20.231 M | |
| Total current liabilities | 24.443 M | 23.435 M | 22.653 M | 23.621 M | 20.340 M | 8.564 M | 8.038 M | 9.616 M | |
| Accounts Payable | 7.918 M | 8.418 M | 4.067 M | 4.389 M | 6.134 M | 3.220 M | 1.378 M | 3.176 M | |
| Other liabilities | 92.213 M | 90.459 M | 64.545 M | 64.545 M | 64.545 M | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 92.213 M | 90.459 M | 64.545 M | 64.545 M | 64.545 M | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 52.413 M | 37.308 M | 48.374 M | 34.354 M | 24.624 M | 81.361 M | 59.488 M | 51.029 M | |
| Common stock | 125.434 M | 133.255 M | 133.261 M | 6.663 M | 6.663 M | 6.663 M | 6.663 M | 6.663 M | |
| Retained earnings | -374.159 M | -390.783 M | -380.530 M | -395.968 M | -405.997 M | -349.623 M | -360.686 M | -369.813 M |